Search details
1.
Antibody-drug conjugates in lung and breast cancer: current evidence and future directions-a position statement from the ETOP IBCSG Partners Foundation.
Ann Oncol
; 2024 Apr 20.
Article
in English
| MEDLINE | ID: mdl-38648979
2.
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Ann Oncol
; 34(4): 397-409, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36709040
3.
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Ann Oncol
; 34(10): 885-898, 2023 10.
Article
in English
| MEDLINE | ID: mdl-37597578
4.
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Ann Oncol
; 33(3): 321-329, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34954044
5.
The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
Ann Oncol
; 32(10): 1236-1244, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34311075
6.
A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
Ann Oncol
; 32(5): 652-660, 2021 05.
Article
in English
| MEDLINE | ID: mdl-33539944
7.
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
Ann Oncol
; 32(8): 983-993, 2021 08.
Article
in English
| MEDLINE | ID: mdl-34272041
8.
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
Ann Oncol
; 32(10): 1256-1266, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34384882
9.
Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer.
Ann Oncol
; 31(5): 582-589, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32178964
10.
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study.
Ann Oncol
; 31(10): 1359-1365, 2020 10.
Article
in English
| MEDLINE | ID: mdl-32652112
11.
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study.
Ann Oncol
; 31(5): 569-581, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32278621
12.
Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning.
Semin Cancer Biol
; 52(Pt 2): 151-157, 2018 10.
Article
in English
| MEDLINE | ID: mdl-29990622
13.
Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.
Ann Oncol
; 30(10): 1638-1646, 2019 10 01.
Article
in English
| MEDLINE | ID: mdl-31400196
14.
Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.
Ann Oncol
; 30(12): 1941-1949, 2019 12 01.
Article
in English
| MEDLINE | ID: mdl-31566659
15.
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 405-411, 2019 03 01.
Article
in English
| MEDLINE | ID: mdl-30475947
16.
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Ann Oncol
; 30(3): 397-404, 2019 03 01.
Article
in English
| MEDLINE | ID: mdl-30475950
17.
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.
Ann Oncol
; 30(2): 236-242, 2019 02 01.
Article
in English
| MEDLINE | ID: mdl-30590484
18.
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329].
Ann Oncol
; 34(7): 630, 2023 Jul.
Article
in English
| MEDLINE | ID: mdl-36564285
19.
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Ann Oncol
; 29(4): 1056-1062, 2018 04 01.
Article
in English
| MEDLINE | ID: mdl-29145561
20.
Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Breast Cancer Res Treat
; 171(1): 21-31, 2018 Aug.
Article
in English
| MEDLINE | ID: mdl-29736741